Dear Herm,

Discussion in 'BioDelivery Sciences' started by anonymous, Apr 13, 2019 at 11:44 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Dear Herm,

    Here is a suggestion on how to grow Belbuca, improve the morale of the sales force and stop the mass exodus of good people. The solution? Replace Scott Plesha, Kevin Patton and Monty Buchanan. As the saying goes the fish rots from the head. They have succeeded in demotivating an entire sales force and running the morale and culture of BDSI into the ground. It is no surprise that sales have suffered under their leadership.

    It doesn’t take a paid consultant to figure out the cause and effect relationship between lackluster sales, an unmotivated sales force and high turnover is ineffective leadership.

    The sales force has taken the blame for too long. BDSI certainly isn’t your last stop as a CEO. Symproic is not the silver bullet to jumpstart Belbuca and BDSI. If you want to take this company to new heights as our CEO it is time to take a closer look at your leadership team and make some much needed changes for the overall health and future of BDSI. Your shareholders and we the sales force will thank you for it.
     

  2. anonymous

    anonymous Guest

    100% accurate.
     
  3. anonymous

    anonymous Guest

    Spot on!!
     
  4. anonymous

    anonymous Guest

    Lick my ballz ho mo janitor From political board
     
  5. anonymous

    anonymous Guest

    agreed with original poster

    need to get more in line with true pharma and at a minimum have a corporate and gas card

    maybe shrink some territories as well, have found driving 3-4 hours doesn't allow for much selling time
     
  6. anonymous

    anonymous Guest

    What might have worked in the beginning w/the leadership at BDSI is not working now that the company has grown and built out its infrastructure. Their scare tactics are played out.
     
  7. anonymous

    anonymous Guest

    The replacement of SP, KP and MB is long overdue. Salix 2.0 isn’t working.
     
  8. anonymous

    anonymous Guest

    The ship is sinking with those three running things. They are doing such a great job that insiders like KK dumped 2,000,000 shares of stock. After acquiring the rights to Symproic the stock is moving in the opposite direction. Not good. It’s time to make some changes at the top starting with Plesha, Patton and Buchanan!
     
  9. anonymous

    anonymous Guest

    ATTN CEO:

    Kevin Patten is an HR liability to BDSI and detrimental to the performance of the West.

    For a brief history lesson on Kevin Patten google:

    KP+Salix+CafePharma OR
    Kevin Patten+Salix+CafePharma

    New company. Same old Kevin.
    Same unethical and unprofessional HR behavior.
     
  10. anonymous

    anonymous Guest

    Dear Herm, Buy AQST! Could be a good fit and add to the empty pipeline. A pipeline could lead to a higher multiple from Wall Street. Their technology is similar, and they are looking into some interesting therapeutic categories.
     
  11. anonymous

    anonymous Guest

    Buy?! We’re for sale if the price is right. So far, no takers.Buyers have approached to buy individual assets but the BOD’s said it’s all or nothing.Several potential buyers have walked away.That should tell us something.
     
  12. anonymous

    anonymous Guest

    Nobody is going to buy BDSI because it has a single product that is an opioid. For big companies, it is not worth the risk. Big companies get sued because they have big money. Nobody wants that liability. Therefore, BDSI must be the buyer.
     
  13. anonymous

    anonymous Guest

    BDSI has more than just 1 product...
     
  14. anonymous

    anonymous Guest

    Ok. Two viable products. Little else, and the VAST majority is one product.
     
  15. anonymous

    anonymous Guest

    You do know that we own more than two products.